Contents

Volume 94 Issue 6 | JNNP June 2023

Editorial commentary
409 Blood biomarkers: ready for clinical practice?
E Coulthard, A A Hossein

Neurodegeneration
411 Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function
S Lehmann, S Schraut-Maschke, J-S Vidal, C Delaby, F Blanc, C Paquet, B Allissaint, S Bombois, A Gabelle, O Hanon

420 Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic

428 Elevated plasma p-tau181 levels unrelated to Alzheimer’s disease pathology in amyotrophic lateral sclerosis
V Vacciana, A Massangelo, C Zenesini, S Biaiardi, P Avoni, B Poliachi, S Capellari, F Salvi, R Liguori, P Parchi, on behalf of the BoReALS group

436 GSN gene frameshift mutations in Alzheimer’s disease

448 Structural and functional changes in the retina in Parkinson’s disease
J N Alves, B U Wester, A Højland, S S Weil, S S Dalal

Cognitive neurology
457 Cognitive performance is associated with glomerular filtration rate in patients with chronic kidney disease: results from the CKD-REIN cohort

Neuromuscular
467 Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis

474 Effectiveness of an outpatient rehabilitation programme in patients with neuralgic amyotrophy and scapular dyskenisia: a randomised controlled trial
R M J Janssen, R Listenhöwer, E H C Cup, N van Allen, J Sjöqvist, R C Helmich, I G M Cameron, A C H Geurts, B G M van Engelen, M J L Graff, J T Gooskuis

Multiple sclerosis
482 Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis

487 Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis

PostScript
494 Letters

More Contents ▶